The Vanguard Group, Inc. recently announced the acquisition of new stake in Millendo Therapeutics Inc. (NASDAQ:MLND). The institutional investor has increased its shareholding in the Healthcare company by 0.06% to 0.59 million shares with purchase of 378.0 shares. This fresh investment now brings its stake to 3.09% valued currently at $1.56 million. In addition, BlackRock Fund Advisors raised its holdings by 90715.0 to 0.55 million shares. And Citadel Advisors LLC has lifted its position to 0.37 million shares – to 0.37 million shares.
With over 0.44 million Millendo Therapeutics Inc. (MLND) shares trading Thursday and a closing price of $1.66 on the day, the dollar volume was approximately $0.73 million. The shares have shown a negative weekly performance of -2.92% and its price on 07/09/20 lost nearly -1.19%. Currently, there are 18.45M common shares owned by the public and among those 17.46M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for MLND have a consensus price objective of $4.33. The analysts have set the share’s price value over the next 12 months at a high of $5.00 and a low of $3.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Millendo Therapeutics Inc. stock is 1.70 for the next 12 months. The estimated low will see the stock gain 44.67% over that period. But an upside of 66.8% will see the stock hit the forecast high price target while mean target price for the stock is $5.00.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Millendo Therapeutics Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.4 million shares of the company’s stock, all valued at over $1.05 million. The company has a total holdings of about 2.09% of the shares outstanding. iShares Russell 2000 ETF bought 1908.0 shares to see its total holdings expand to 0.19 million shares valued at over $0.51 million and representing 1.02% of the shares outstanding. Vanguard Extended Market Index Fu sold 386.0 shares to bring its total holdings to over 0.14 million shares at a value of $0.37 million. Vanguard Extended Market Index Fu now owns shares totaling to 0.73% of the shares outstanding.
Shares of Millendo Therapeutics Inc. (NASDAQ: MLND) opened at $1.71, up $0.03 from a prior closing price of $1.68. However, the script later closed the day at $1.66, down -1.19%. The company’s stock has a 5-day price change of -2.92% and 16.08% over the past three months. MLND shares are trading -75.37% year to date (YTD), with the 12-month market performance down to -85.96% lower. It has a 12-month low price of $1.26 and touched a high of $12.26 over the same period. Currently, 0.44 million shares have been traded, compared to an average intraday trading volume of 1.69 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -19.88%, -16.59%, and -69.97% respectively.
Institutional ownership of Millendo Therapeutics Inc. (NASDAQ: MLND) shares accounts for 71.50% of the company’s 18.45M shares outstanding. Mutual fund holders own 35.29%, while other institutional holders and individual stakeholders account for 6.56% and 17.33% respectively.
It has a market capitalization of $31.37M and a beta (3y monthly) value of 1.48. The stock’s earnings-per-share (ttm) stands at -$3.12. The company has a Quick Ratio of 5.80 with the debt-to-equity ratio at 0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.97% over the week and 12.88% over the month.
Analysts forecast that Millendo Therapeutics Inc. (MLND) will achieve an EPS of -$0.55 for the current quarter, -$0.46 for the next quarter and -$1.36 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.64 while analysts give the company a high EPS estimate of -$0.47. Comparatively, EPS for the current quarter was -$0.74 a year ago. Earnings per share for the fiscal year are expected to increase by 81.50%, and 35.50% over the next financial year. EPS over the next five years should compared to 37.00% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Millendo Therapeutics Inc. (MLND) as a “Strong Buy” at a consensus score of 1.70. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 1 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the MLND, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on May 29, 2020, with the firm’s price target at $6. Oppenheimer coverage for the Millendo Therapeutics Inc. (MLND) stock in a research note released on April 07, 2020 offered a Perform rating with a price target of. Wedbush was of a view on April 06, 2020 that the stock is Neutral, while Citigroup gave the stock Buy rating on February 07, 2020 $23. ROTH Capital on their part issued Buy rating on January 10, 2020.